Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies

Author(s): Senthamil R. Selvan, John P. Dowling, William K. Kelly, Jianqing Lin

Journal Name: Current Cancer Drug Targets

Volume 16 , Issue 9 , 2016

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Indoleamine 2,3-dioxygenase (IDO) is a heme-containing oxidoreductase that catalyzes the initial and rate-limiting step in the breakdown of non-dietary tryptophan. The biology and immunomodulatory role for IDO is discussed in this review with a focus on its interaction with immune cells and its potential therapeutic target in the clinic. IDO has been revealed to be a central regulator of immune responses in a broad variety of physiological and pathological settings, mostly serving as a multifaceted negative feedback mechanism, to self-regulate immune responses. IDO is considered a therapeutic target in cancer and the use of IDO inhibitors as single agent or in combination with other treatment modalities are under active investigation.

Keywords: Cancer immunotherapy, combination therapy, indoleamine 2, 3-dioxygenase (IDO), IDO inhibitors, immune tolerance.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Published on: 29 October, 2015
Page: [755 - 764]
Pages: 10
DOI: 10.2174/1568009615666151030102250
Price: $65

Article Metrics

PDF: 191
HTML: 18
PRC: 2